DK2968483T3 - Subkutan indgivelse af adamts13 - Google Patents

Subkutan indgivelse af adamts13 Download PDF

Info

Publication number
DK2968483T3
DK2968483T3 DK14719469.0T DK14719469T DK2968483T3 DK 2968483 T3 DK2968483 T3 DK 2968483T3 DK 14719469 T DK14719469 T DK 14719469T DK 2968483 T3 DK2968483 T3 DK 2968483T3
Authority
DK
Denmark
Prior art keywords
subcutan
adamts13
submission
subcutan submission
Prior art date
Application number
DK14719469.0T
Other languages
Danish (da)
English (en)
Inventor
Alexandra Nathalie Kopic
Werner Hoellriegl
Barbara Plaimauer
Hanspeter Rottensteiner
Eva-Maria Muchitsch
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK2968483T3 publication Critical patent/DK2968483T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24087ADAMTS13 endopeptidase (3.4.24.87)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
DK14719469.0T 2013-03-15 2014-03-13 Subkutan indgivelse af adamts13 DK2968483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Publications (1)

Publication Number Publication Date
DK2968483T3 true DK2968483T3 (da) 2022-02-14

Family

ID=50549463

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14719469.0T DK2968483T3 (da) 2013-03-15 2014-03-13 Subkutan indgivelse af adamts13

Country Status (18)

Country Link
US (4) US9611467B2 (enExample)
EP (2) EP3960196A1 (enExample)
JP (4) JP6484216B2 (enExample)
KR (5) KR102102087B1 (enExample)
CN (2) CN114259558A (enExample)
AU (5) AU2013203062C1 (enExample)
BR (1) BR112015023542A8 (enExample)
CA (1) CA2905058A1 (enExample)
DK (1) DK2968483T3 (enExample)
EA (2) EA034546B1 (enExample)
ES (1) ES2906550T3 (enExample)
IL (3) IL241305B (enExample)
MX (2) MX380485B (enExample)
PL (1) PL2968483T3 (enExample)
PT (1) PT2968483T (enExample)
SG (3) SG10201707074TA (enExample)
TW (4) TWI690326B (enExample)
WO (1) WO2014151968A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
CN116159130B (zh) 2016-08-04 2025-09-09 武田药品工业株式会社 使用adamts13治疗、改善和/或预防镰状细胞病、急性肺损伤和/或急性呼吸窘迫综合征中的血管阻塞危象
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US20230203469A1 (en) * 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
KR20230038658A (ko) * 2020-05-25 2023-03-21 산퀸 아이피 비.브이. Adamts13 단백질 변형체 및 그것의 용도
JP2023549878A (ja) * 2020-11-18 2023-11-29 グリーン・クロス・コーポレイション 自己抗体に対する回避率又は活性が向上したadamts13バリアント
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
US7763430B2 (en) 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
CA2606351C (en) * 2005-06-17 2016-12-13 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するadamts13含有組成物
US20090317375A1 (en) * 2008-05-12 2009-12-24 Immune Disease Institute, Inc. Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
PL4218797T3 (pl) * 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
CN103097522A (zh) * 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Also Published As

Publication number Publication date
MX2015012783A (es) 2016-04-28
AU2013203062A1 (en) 2014-10-02
MX380485B (es) 2025-03-12
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
IL241305B (en) 2020-04-30
BR112015023542A2 (pt) 2017-07-18
CN114259558A (zh) 2022-04-01
EP2968483B1 (en) 2021-12-01
IL273365B (en) 2022-05-01
US10413600B2 (en) 2019-09-17
US20220080032A1 (en) 2022-03-17
AU2016231547B2 (en) 2018-03-15
KR20160016756A (ko) 2016-02-15
SG10201707074TA (en) 2017-10-30
US11185575B2 (en) 2021-11-30
JP7238088B2 (ja) 2023-03-13
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
EP2968483A1 (en) 2016-01-20
IL273365A (en) 2020-05-31
IL290486B2 (en) 2023-08-01
AU2013203062B2 (en) 2016-06-23
TW201513881A (zh) 2015-04-16
KR102218489B1 (ko) 2021-02-22
AU2020202738A1 (en) 2020-05-14
AU2020202738B2 (en) 2022-06-09
SG11201507271QA (en) 2015-10-29
NZ751610A (en) 2020-11-27
KR20200041394A (ko) 2020-04-21
WO2014151968A8 (en) 2015-10-15
AU2018203665B2 (en) 2020-01-30
CA2905058A1 (en) 2014-09-25
TWI786563B (zh) 2022-12-11
JP2019142850A (ja) 2019-08-29
SG10202001227QA (en) 2020-03-30
HK1220131A1 (zh) 2017-04-28
EA201992832A1 (ru) 2020-05-31
KR20220027266A (ko) 2022-03-07
PL2968483T3 (pl) 2022-04-04
IL290486B1 (en) 2023-04-01
TWI740207B (zh) 2021-09-21
TW202017591A (zh) 2020-05-16
BR112015023542A8 (pt) 2019-12-03
IL290486A (en) 2022-04-01
KR20210021107A (ko) 2021-02-24
EP3960196A1 (en) 2022-03-02
KR20190022926A (ko) 2019-03-06
WO2014151968A1 (en) 2014-09-25
IL241305A0 (en) 2015-11-30
AU2016231547A1 (en) 2016-10-06
EA034546B1 (ru) 2020-02-19
US20140271611A1 (en) 2014-09-18
KR102513872B1 (ko) 2023-03-27
TWI690326B (zh) 2020-04-11
JP6998333B2 (ja) 2022-02-10
TW202138003A (zh) 2021-10-16
JP6484216B2 (ja) 2019-03-13
US11779635B2 (en) 2023-10-10
JP2022027991A (ja) 2022-02-14
US9611467B2 (en) 2017-04-04
KR102102087B1 (ko) 2020-04-20
US20170224785A1 (en) 2017-08-10
MX2021002513A (es) 2021-04-28
KR102365936B1 (ko) 2022-02-23
PT2968483T (pt) 2022-02-23
US20200101144A1 (en) 2020-04-02
JP2023071821A (ja) 2023-05-23
EA201591758A8 (ru) 2017-03-31
AU2022211908A1 (en) 2022-09-01
ES2906550T3 (es) 2022-04-19
AU2018203665A1 (en) 2018-06-14
AU2013203062C1 (en) 2018-06-28
EA201591758A1 (ru) 2016-03-31
NZ749570A (en) 2020-11-27
JP2016517421A (ja) 2016-06-16

Similar Documents

Publication Publication Date Title
IL269227B (en) Solid forms of treprostinil
DK3087183T3 (da) Modulation af angiopoietin-3-lignende ekspression
DK2968208T3 (da) Behandling af kataplexi
DK3342773T3 (da) Syk-hæmmere
DK2961388T3 (da) Kombinationer af lægemidler
DK2970954T3 (da) Modifikation af polypeptider
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2968483T3 (da) Subkutan indgivelse af adamts13
DK3079750T3 (da) Udskyllelige katetre
PT2953948T (pt) Antagonistas de integrina fluorada
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK2965026T3 (da) Generering af slushice
HUE037417T2 (hu) Szubsztituált imidazopiridazinok
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
DK3620198T3 (da) Udskyllelige katetre
DK3063264T3 (da) Tørring af mikroorganismer
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
UA27558S (uk) Лінза
DK2822301T3 (da) Bestemmelse af individuelle HRTF
DK3071227T3 (da) Fiskevaccine